title: Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
authors.affiliation: Goodheart Institute and Foundation, European Working Group on Myeloproliferative Neoplasms, Rotterdam, The Netherlands.
authors.forename: Jan Jacques
authors.initials: JJ
authors.lastname: Michiels
authors.forename: Achille
authors.initials: A
authors.lastname: Pich
authors.forename: Hendrik
authors.initials: H
authors.lastname: De Raeve
authors.forename: Alain
authors.initials: A
authors.lastname: Gadisseur
mesh_terms: D000368:Aged; D000483:Alleles; D001549:Benzamides / Q000627:therapeutic use; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use; D010976:Platelet Count; D011087:Polycythemia Vera / Q000175:diagnosis* / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D053614:Janus Kinase 2; C021139:anagrelide; D006918:Hydroxyurea